Michael A. Gleason is a partner with Jones Day based in the firm’s Washington, D.C. office. For 15 years, he has been involved in some of the most significant transactions to recently come before the antitrust agencies. He counsels clients on antitrust matters before U.S. and international enforcement agencies, including cross-border M&A transactions and government investigations, as well as antitrust litigation. Michael has represented a variety of clients before the U.S. Department of Justice (DOJ), Federal Trade Commission (FTC), state, and international antitrust enforcers and has extensive experience in a range of industries, including agriculture, health care (providers and payers), pharmaceuticals, medical devices, software, tech platforms, chemicals, mining, defense, commodities, and food products, among others. His transactional work includes counseling clients at every stage of a deal, including premerger planning, regulatory filings, investigations, litigation, as well as post-closing investigations. Michael also frequently advises clients on a variety of antitrust issues, including competitor and vertical collaborations, information sharing, distribution arrangements, licensing, and single-firm conduct.
FAQ About the FTC’s Controversial New “Unfair Methods of Competition” PolicyJones Day, Craig Waldman, Michael Gleason, Lin Kahn, Jeremy Morrison and James Burnham, November 2022
The US FTC resurrects the unilateral pre-approval in merger investigation settlements to halt future anticompetitive mergersConcurrences Bulletin, Michael A. Gleason, Lin W. Kahn, Bruce McDonald, Jeremy P. Morrison and Craig A. Waldman, 25 October 2021, e-Competitions
Attorney-client privilege and common interest privilege in antitrust merger reviewThe M&A Lawyer, Pamela L. Taylor and Michael A. Gleason, October 2020, Volume 24, Issue 9